Visit CMR at Booth 202 at NCoBC 2025

CMR will be exhibiting the LumaGEM® Molecular Breast Imaging (MBI) System at Booth 202

MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice. Dibble et al. AJR 2020; 215:277–284

RELATED TALKS AT NCoBC

IMAGING SESSION TALKS
SATURDAY, MARCH 22

10:35 – 11:05 AM | Molecular Breast Imaging

Katie Hunt, MD

1:30 – 2:00 PM | Debate: MBI, CEM, AbrMRI

Katie Hunt, MD, Emily Conant, MD, Victoria Mango, MD

SURVIVORS & ADVOCATES SUMMIT TALKS
SUNDAY, MARCH 23

10:30 – 11:00 AM | Facing Challenges and Embracing Opportunities in Today’s Changing World: The Power of Self Advocacy

Leslie Ferris Yerger, MBA

11:00 – 11:30 AM | Navigating Dense Breasts: Exploring Advanced Imaging Modalities for Effective Screening

Katie Hunt, MD

5:00 PM | Closing Remarks